Evaluation Of Celecoxib In Combination With Docetaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer Patients Previously Treated With Platinum Based Chemotherapy
18 Years
N/A
Both
Lung Cancer
Trial Information
Evaluation Of Celecoxib In Combination With Docetaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer Patients Previously Treated With Platinum Based Chemotherapy
OBJECTIVES:
- Determine the efficacy and feasibility of celecoxib combined with docetaxel in patients
with advanced non-small cell lung cancer previously treated with platinum-based
chemotherapy.
- Determine the response rate of patients treated with this regimen.
- Determine the toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral celecoxib twice daily (beginning on day -7 of the first course) and
docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease
progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive
2 additional courses after CR. Patients who achieve stable disease (SD) or a partial
response (PR) receive a minimum of 2 additional courses after SD or PR. At the discretion of
the treating physician, patients then receive maintenance therapy comprising celecoxib only.
Patients who discontinue therapy for disease progression or unacceptable toxicity are
followed for at least 6 months.
PROJECTED ACCRUAL: A total of 21-39 patients will be accrued for this study within 13-28
months.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of stage IIIA, IIIB, or IV non-small cell lung cancer
- Disease progression during or after 1 or more platinum-based chemotherapy
regimens
- Measurable or evaluable disease
- No symptomatic or untreated brain or leptomeningeal metastases
- Previously treated patients must be neurologically stable for 4 weeks after
completion of appropriate therapy
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- SWOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 8 g/dL
Hepatic:
- Bilirubin no greater than upper limit of normal (ULN)
- AST/ALT no greater than ULN (or no greater than 2.5 times ULN if alkaline phosphatase
no greater than ULN)
- Alkaline phosphatase no greater than ULN (or no greater than 5 times ULN if AST/ALT
no greater than ULN)
- No history of chronic hepatitis of any duration
Renal:
- Creatinine no greater than ULN
Cardiovascular:
- No uncontrolled congestive heart failure
- No uncontrolled angina
- No myocardial infarction and/or stroke within the past 6 months
- No active thromboembolic event within the past 4 weeks
Gastrointestinal:
- No gastrointestinal bleeding within the past 6 months
- No history of peptic ulcer disease
Other:
- No prior hypersensitivity reaction to docetaxel or other drugs formulated with
polysorbate 80
- No prior allergy to any non-steroidal anti-inflammatory drug
- No other prior or concurrent malignancy within the past 3 years except adequately
treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix
- No grade 2 or greater peripheral neuropathy
- No active infection
- No other serious concurrent medical illness
- No history of dementia, active psychiatric disorder, or other condition that would
interfere with ability to take oral medication or preclude compliance with study
- HIV negative
- Must weigh at least 50 kg (110 pounds)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- See Disease Characteristics
- At least 4 weeks since prior chemotherapy
- Prior paclitaxel allowed
- No prior docetaxel
Endocrine therapy:
- At least 3 days since prior steroids
Radiotherapy:
- At least 4 weeks since prior radiotherapy
- No prior radiotherapy to target lesion
Surgery:
- At least 4 weeks since prior major surgery
Other:
- Prior intermittent use of non-steroidal anti-inflammatory drugs (NSAIDs), including
rofecoxib or celecoxib, allowed
- At least 1 week since prior fluconazole
- No recent prior NSAIDs, including rofecoxib or celecoxib, for a duration of more than
30 consecutive days
- No concurrent fluconazole or lithium
- No other concurrent NSAIDs except aspirin administered at a dose of no more than 325
mg/day for cardiovascular conditions
- No other concurrent cyclo-oxygenase-2 inhibitors
- No other concurrent investigational agents
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Efficacy of combining Celecoxib with Docetaxel
Outcome Description:
Blood levels of VEGF & PGE2
Outcome Time Frame:
Weeks 1 , 2 and 3
Safety Issue:
No
Principal Investigator
Shirish M. Gadgeel, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Barbara Ann Karmanos Cancer Institute
Authority:
United States: Federal Government
Study ID:
CDR0000069164
NCT ID:
NCT00030420
Start Date:
October 2001
Completion Date:
February 2008
Related Keywords:
- Lung Cancer
- recurrent non-small cell lung cancer
- stage IIIA non-small cell lung cancer
- stage IIIB non-small cell lung cancer
- stage IV non-small cell lung cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|---|
| Barbara Ann Karmanos Cancer Institute | Detroit, Michigan 48201 |
